Radiant Business Consortium Limited (RBCL) and Roche Bangladesh Limited have formally entered into a co-promotion agreement, marking an important milestone in their long-standing collaboration to strengthen healthcare delivery in Bangladesh, effective from November 12, 2023.
This strategic partnership is designed to expand access to innovative pharmaceutical therapies, particularly for the treatment of cancer and ophthalmological disorders, and to enhance public awareness of advanced treatment options available to patients across the country.
By combining the strengths of both organizations in research, development, marketing, and distribution, the collaboration aims to accelerate the availability of high-quality, life-saving medicines and deliver meaningful improvements in healthcare outcomes for patients in Bangladesh.
Mr. Md. Nasser Shahrear Zahedee, Chairman of Radiant Pharmaceuticals Limited, described the agreement as a landmark development for the country’s pharmaceutical sector and a major step forward in strengthening Bangladesh’s healthcare ecosystem.
Mr. Mark Heeb, Country Manager of Roche Bangladesh, expressed strong confidence in the partnership, stating that the collaboration reflects a shared commitment to advancing healthcare solutions and making a meaningful difference in the lives of patients throughout the country.
Both organizations look forward to the long-term positive impact this partnership will have on Bangladesh’s healthcare landscape and the well-being of its people.